De-oncogenic HPV E6/E7 vaccine gets enhanced antigenicity and promotes tumoricidal synergy with cisplatin

Acta Biochimica et Biophysica Sinica

Volumn 46, Issue 1, 2014, Pages 6-14

  Chen, Shaochun ^a,b   Liao, Chaowei ^c   Lai, Yiukay ^d,e   Fan, Yan ^a   Lu, Gang ^b   Wang, Hua ^b   Zhang, Xiaoai ^a   Lin, Marie C M ^b   Leng, Shuilong ^f   Kung, Hsiang Fu ^b  

^a KUNMING MEDICAL UNIVERSITY   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c Miaoli 999079   (China)

^d NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^e Herbcopoeia YNBY Laboratories   (China)

^f GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

cancer vaccine; cisplatin; papillomavirus E6 protein; papillomavirus E7 protein; uterine cervical neoplasms

Indexed keywords

ANTINEOPLASTIC AGENT; BACTERIAL TOXIN; CANCER VACCINE; CISPLATIN; DNA BINDING PROTEIN; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18; EXOTOXIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; PAPILLOMAVIRUS E6 PROTEIN; PROTEIN E7; TOXA PROTEIN, PSEUDOMONAS AERUGINOSA; VIRULENCE FACTOR; WART VIRUS VACCINE;

ANIMAL; ARTICLE; DRUG POTENTIATION; IMMUNOLOGY; MOUSE; TUMOR CELL LINE; UTERINE CERVIX TUMOR;

CANCER VACCINE; CISPLATIN; PAPILLOMAVIRUS E6 PROTEIN; PAPILLOMAVIRUS E7 PROTEIN; UTERINE CERVICAL NEOPLASMS;

ADP RIBOSE TRANSFERASES; ANIMALS; ANTINEOPLASTIC AGENTS; BACTERIAL TOXINS; CANCER VACCINES; CELL LINE, TUMOR; CISPLATIN; DNA-BINDING PROTEINS; DRUG SYNERGISM; EXOTOXINS; MICE; ONCOGENE PROTEINS, FUSION; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS VACCINES; VIRULENCE FACTORS;

EID: 84891369874     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmt121     Document Type: Article

References (42)

1. Moody CA and Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer 2010, 10: 550-560.
2. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC and Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007, 65: 641-649.
3. Chung CH and Gillison ML. Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications. Clin Cancer Res 2009, 15: 6758-6762.
4. Parkin DM and Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 2006, 24: 11-25.
5. Lehoux M, D'Abramo CM and Archambault J. Molecular mechanisms of human papillomavirus-induced carcinogenesis. Public Health Genomics 2009, 12: 268-280.
6. Yugawa T and Kiyono T. Molecular mechanisms of cervical carcinogenesis by high-risk human papillomaviruses: novel functions of E6 and E7 onco-proteins. Rev Med Virol 2009, 19: 97-113.
7. Sima N, Wang S, Wang W, Kong D, Xu Q, Tian X and Luo A, et al. Antisense targeting human papillomavirus type 16 E6 and E7 genes contributes to apoptosis and senescence in SiHa cervical carcinoma cells. Gynecol Oncol 2007, 106: 299-304.
8. Yoshinouchi M, Yamada T, Kizaki M, Fen J, Koseki T, Ikeda Y and Nishihara T, et al. In vitro and in vivo growth suppression of human papillo-mavirus 16-positive cervical cancer cells by E6 siRNA. Mol Ther 2003, 8: 762-768.
9. McLaughlin-Drubin ME and Munger K. Oncogenic activities of human papillomaviruses. Virus Res 2009, 143: 195-208.
10. Narisawa-Saito M and Kiyono T. Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins. Cancer Sci 2007, 98: 1505-1511.
11. Boulet G, Horvath C, Vanden Broeck D, Sahebali S and Bogers J. Human papillomavirus: E6 and E7 oncogenes. Int J Biochem Cell Biol 2007, 39: 2006-2011.
12. Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007, 369: 1861-1868.
13. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM and Jenkins D, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006, 367: 1247-1255.
14. Cui Z and Huang L. Liposome-polycation-DNA (LPD) particle as a carrier and adjuvant for protein-based vaccines: therapeutic effect against cervical cancer. Cancer Immunol Immunother 2005, 54: 1180-1190.
15. Sharma RK, Srivastava AK, Yolcu ES, MacLeod KJ, Schabowsky RH, Madireddi S and Shirwan H. SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model. Vaccine 2010, 28: 5794-5802.
16. Zwaveling S, Ferreira Mota SC, Nouta J, Johnson M, Lipford GB, Offringa R and Vander Burg SH, et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 2002, 169: 350-358.
17. Kim D, Hung CF, Wu TC and Park YM. DNA vaccine with alpha-galacto- sylceramide at prime phase enhances anti-tumor immunity after boosting with antigen-expressing dendritic cells. Vaccine 2010, 28: 7297-7305.
18. Kim TW, Hung CF, Boyd DA, He L, Lin CT, Kaiserman D and Bird PI, et al. Enhancement of DNA vaccine potency by coadministration of a tumor antigen gene and DNA encoding serine protease inhibitor-6. Cancer Res 2004, 64: 400-405.
19. Peng S, Monie A, Kang TH, Hung CF, Roden R and Wu TC. Efficient delivery of DNA vaccines using human papillomavirus pseudovirions. Gene Ther 2010, 17: 1453-1464.
20. Preville X, Ladant D, Timmerman B and Leclerc C. Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein. Cancer Res 2005, 65: 641-649.
21. Hung CF, Cheng WF, Hsu KF, Chai CY, He L, Ling M and Wu TC. Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Res 2001, 61: 3698-3703.
22. Liao CW, Chen CA, Lee CN, Su YN, Chang MC, Syu MH and Hsieh CY, et al. Fusion protein vaccine by domains of bacterial exotoxin linked with a tumor antigen generates potent immunologic responses and antitumor effects. Cancer Res 2005, 65: 9089-9098.
23. Ohlschläger P, Pes M, Osen W, Dürst M, Schneider A, Gissmann L and Kaufmann AM. An improved rearranged human papillomavirus type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response. Vaccine 2006, 24: 2880-2893.
24. Huang CY, Chen CA, Lee CN, Chang MC, Su YN, Lin YC and Hsieh CY, et al. DNA vaccine encoding heat shock protein 60 co-linked to HPV16 E6 and E7 tumor antigens generates more potent immunotherapeutic effects than respective E6 or E7 tumor antigens. Gynecol Oncol 2007, 107: 404-412.
25. Huang CY, Chen JJ, Shen KY, Chang LS, Yeh YC, Chen IH and Chong P, et al. Recombinant lipidated HPV E7 induces a Th-1-biased immune response and protective immunity against cervical cancer in a mouse model. PLoS ONE 2012, 7: e40970.
26. Cheng WF, Hung CF, Chai CY, Hsu KF, He L, Ling M and Wu TC. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest 2001, 108: 669-678.
27. Cheng WF, Hung CF, Hsu KF, Chai CY, He L, Polo JM and Slater LA, et al. Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion. Hum Gene Ther 2002, 13: 553-568.
28. Cheng WF, Hung CF, Hsu KF, Chai CY, He L, Ling M and Slater LA, et al. Enhancement of Sindbis virus self-replicating RNA vaccine potency by targeting antigen to endosomal/lysosomal compartments. Hum Gene Ther 2001, 12: 235-252.
29. Bae SH, Park YJ, Park JB, Choi YS, Kim MS and Sin JI. Therapeutic synergy of human papillomavirus E7 subunit vaccines plus cisplatin in an animal tumor model: causal involvement of increased sensitivity of cisplatin-treated tumors to CTL-mediated killing in therapeutic synergy. Clin Cancer Res 2007, 13: 341-349.
30. Peng S, Tomson TT, Trimble C, He L, Hung CF and Wu TC. A combination of DNA vaccines targeting human papillomavirus type 16 E6 and E7 generates potent antitumor effects. Gene Ther 2006, 13: 257-265.
31. Münger K, Basile JR, Duensing S, Eichten A, Gonzalez SL, Grace M and Zacny VL. Biological activities and molecular targets of the human papillo-mavirus E7 oncoprotein. Oncogene 2001, 20: 7888-7898.
32. Wieking BG, Vermeer DW, Spanos WC, Lee KM, Vermeer P, Lee WT and Xu Y, et al. A non-oncogenic HPV 16 E6/E7 vaccine enhances treatment of HPV expressing tumors. Cancer Gene Ther 2012, 19: 667-674.
33. Gao Q, Singh L, Kumar A, Srinivasan S, Wazer DE and Band V. Human papillomavirus type 16 E6-induced degradation of E6TP1 correlates with its ability to immortalize human mammary epithelial cells. J Virol 2001, 75: 4459-4466.
34. Zanier K, Charbonnier S, Sidi AO, McEwen AG, Ferrario MG, Poussin-Courmontagne P and Cura V, et al. Structural basis for hijacking of cellular LxxLL motifs by papillomavirus E6 oncoproteins. Science 2013, 339: 694-698.
35. Smahel M, Sima P, Ludvikova V and Vonka V. Modified HPV16 E7 genes as DNA vaccine against E7-containing oncogenic cells. Virology 2001, 281: 231-238.
36. Bauer S, Heeg K, Wagner H and Lipford GB. Identification of H-2Kb binding and immunogenic peptides from human papilloma virus tumour antigens E6 and E7. Scand J Immunol 1995, 42: 317-323.
37. Frazer IH, Thomas R, Zhou J, Leggatt GR, Dunn L, McMillan N and Tindle RW, et al. Potential strategies utilised by papillomavirus to evade host immunity. Immunol Rev 1999, 168: 131-142.
38. Kim KH, Greenfield WW, Cannon MJ, Coleman HN, Spencer HJ and Nakagawa M. CD4 T-cell response against human papillomavirus type 16 E6 protein is associated with a favorable clinical trend. Cancer Immunol Immunother 2012, 61: 63-70.
39. de Jong A, van Poelgeest MI, van der Hulst JM, Drijfhout JW, Fleuren GJ, Melief CJ and Kenter G, et al. Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4 T-cell immunity against early antigens E2 and E6. Cancer Res 2004, 64: 5449-5455.
40. Polakova I, Pokorna D, Duskova M and Smahel M. DNA vaccine against human papillomavirus type 16: modifications of the E6 oncogene. Vaccine 2010, 28: 1506-1513.
41. Welters MJ, de Jong A, van den Eeden SJ, van der Hulst JM, Kwappenberg KM, Hassane S and Franken KL, et al. Frequent display of human papillo-mavirus type 16 E6-specific memory T-helper cells in the healthy population as witness of previous viral encounter. Cancer Res 2003, 63: 636-641.
42. Kang TH, Mao CP, Lee SY, Chen A, Lee JH, Kim TW and Alvarez RD, et al. Chemotherapy acts as an adjuvant to convert the tumor microenviron-ment into a highly permissive state for vaccination-induced antitumor immunity. Cancer Res 2013, 73: 2493-2504.